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Abstract
Summary Based on the clinical, BMD, and TBS data of 2380 participants aged ≥ 60 which was gathered during the BEH
program, stage II, we showed that MetS was positively associated with BMD, while a negative or no association was observed
between MetS and TBS depending on the sex and the adjustment model.
Introduction The results of previous reports in regard to the effect of metabolic syndrome (MetS) on bone health are not
conclusive. This study aimed to evaluate the association between MetS with bone mineral density (BMD) and trabecular bone
score (TBS) as an indicator of bone quantity and quality, respectively.
Methods Using a cross-sectional design, this study was carried out based on the data collected during the BEH Program, stage II.
MetS was defined according to NCEP-ATP III criteria. BMD (at the lumbar spine and the hip) and lumbar spine TBS were
assessed by dual-energy X-ray absorptiometry device.
Results The data of 2380 participants (women = 1228, men = 1152) aged ≥ 60 were analyzed. In the fully adjusted regression
models (including BMI), significant associations between MetS and mean BMD were observed across all locations in men (P
values ≤ 0.001) and in the lumbar spine in women (P value = 0.003). In addition, the prevalence of osteoporosis (based on BMD)
was significantly lower in those with MetS than those without MetS in both sexes, even after full adjustments (women, OR =
0.707, P value = 0.013; men, OR = 0.563, P value = 0.001). In contrast, in age-adjusted regression analyses, the prevalence of
degraded bone microarchitecture (TBS ≤ 1.2) was significantly increased in those with MetS than those without, irrespective of
the participants’ sex (P values < 0.05). The mean TBS was also negatively associated with MetS in women (β = − 0.075, P
value = 0.007) but not inmen (β = − 0.052,P value = 0.077), in age-adjusted regressionmodels. However, after including BMI in
the adjusted models, all significant associations between TBS values and MetS disappeared.
Conclusion It seems that a positive association exists between MetS and BMD, while MetS is either not associated or negatively
correlated with bone quality as measured by TBS.
Keywords Metabolic syndrome . Trabecular bone score . Bonemineral densitometry . BMD . TBS
Introduction
Osteoporosis is a skeletal disorder in which the density and
quality of bone are reduced, resulting in an increased risk of
fragility fracture [1]. According to current estimates, osteopo-
rosis affects more than 200 million people across the world
and causes 8.9 million fractures each year [1]. Bone mineral
density (BMD) measured by dual-energy X-ray absorptiome-
try (DXA) is the gold standard for the diagnosis of osteopo-
rosis [2, 3]. However, numerous studies have indicated that
the assessment of bone quantity by BMD alone cannot predict
all the fragility fractures, and therefore, other factors such as
microarchitecture of the bone should be considered for a more
accurate fracture risk assessment [2–4]. Several non-invasive
techniques have been developed for the evaluation of bone
microarchitecture, an index of the bone quality [2, 4–6].
Among these techniques, trabecular bone score (TBS) is a
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more acceptable modality in clinical practice owing to its fea-
sibility and lower costs [2, 7]. TBS is a gray-level texture
measurement obtained from lumbar spine DXA images and
has been shown to improve the fracture risk prediction of
BMD [8].
Metabolic syndrome (MetS) is a medical state defined by
the constellation of several metabolic abnormalities, which is
predominantly associated with insulin resistance and central
obesity [9]. MetS is a prevalent disorder and affects more than
20% of the general population with a growing trend world-
wide [9]. The association of MetS with cardiovascular dis-
eases and type 2 diabetes mellitus (DM) is well established
[9]; however, there are uncertainties about its effect on bone
health [10, 11]. For instance, some studies indicated that MetS
and abdominal obesity, one of the main components of MetS,
are associated with higher BMD and lower facture risk
[12–15]. On the other hand, other studies suggested that these
conditions are associated with lower bone density and quality
as well as higher incidence of osteoporotic fractures [16–20].
In regard to uncertain and controversial pieces of evidence
about the effect of MetS on bone health [10, 21], we aimed to
determine the association of MetS and its components with
bone quantity (based on BMD) as well as bone quality (based
on TBS) in this study.
Materials and methods
Study population
This cross-sectional study was conducted within the frame-
work of Bushehr Elderly Health (BEH) program, stage II
(2015). The details and protocol of the BEH program were
previously described elsewhere [22, 23]. In summary, the
BEH program is a prospective population-based cohort study
performed on a representative sample of the elderly (≥
60 years) in the urban population of Bushehr city, the center
of the Bushehr province, located in the south of Iran, with the
aim of determining the prevalence and risk factors of non-
communicable diseases (NCD), including cardiovascular dis-
ease, musculoskeletal disorders, and cognitive impairment.
Data collection
Demographic and lifestyle data such as physical activity and
smoking habits were obtained, using standard self-reported
questionnaires [22, 23]. A fixed stadiometer and a digital scale
were used for the measurements of height and weight, respec-
tively. The waist circumference (WC) was measured just
above the iliac crest using a stretch-resistant tape. All mea-
surements were read with the precision of 0.1 cm and 0.1 kg.
Bodymass index (BMI) was calculated by the formula weight
(kg)/[height (m)]2. Blood pressure (BP) was measured twice
by a standard mercury sphygmomanometer after 15 min of
rest in the seated position, and then the mean of the two mea-
surements was considered as the participant’s systolic and
diastolic blood pressures.
Fasting blood samples were collected from the participants
following 8–12 h of overnight fast. Fasting plasma glucose
(FPG), total cholesterol (TC), low-density lipoprotein choles-
terol (LDL-C), high-density lipoprotein cholesterol (HDL-C),
and triglycerides (TG) were measured by an auto-analyzer
using commercial kits (ParsAzmun, Karaj, Iran).
The BMD of the femoral neck, total hip, and lumbar spines
(L1-L4) were measured by DXA (Hologic Inc., USA), and the
TBS iNsight® software installed on our DXA machine was
used for the assessment of L1-L4 TBS.
Definitions
MetS was defined according to the revised National
Cholesterol Education Program Adult Treatment Panel III
(NCEP-ATP III) criteria by the presence of ≥ 3 of the follow-
ing criteria: abdominal obesity [WC > 102 cm (men) or >
88 cm (women)]; TG ≥ 150 mg/dl; HDL-C < 40 mg/dl (men)
or < 50 mg/dl (women); BP ≥ 130/85 mmHg or on antihyper-
tensive medications; and FPG ≥ 100 mg/dl or on drug treat-
ment for elevated glucose [24].
Current smoker was defined as one who smokes at least
one cigarette per day or uses a hookah or pipe once daily at the
time of evaluation.
The amount of physical activity was estimated based on
metabolic equivalents (METs) score using a validated ques-
tionnaire for a single measurement of 24-h physical activity on
an average weekday [23, 25].
Based on BMD, osteoporosis was defined as T-score ≤ −
2.5 in the total hip, femoral neck, or lumbar spine [26]. TBS
score ≤ 1.200 was cons idered as degraded bone
microarchitecture in both sexes [27–29].
Ethical considerations
This study was approved by the Ethical Research Committee
(ERC) of Endocrinology and Metabolism Research Institute,
which is affiliated to Tehran University of Medical Sciences
and the ERC of Bushehr University of Medical Sciences.
Informed consent was obtained from all participants.
Statistical analyses
The Kolmogorov-Smirnov test was used for assessing the
normal distribution of continuous variables. Normally distrib-
uted variables were presented as mean ± standard deviation
(SD) and parametric tests such as independent t test or
ANOVA were used for comparing means between groups. P
value for trend was calculated for the assessment of statistical
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significance between means and proportions across ordinal
groups by χ2 for trend. Uni- and multivariable linear and
logistic regression analyses were used to examine the associ-
ation between MetS and bone quantity (based on BMD) as
well as bone quality (based on TBS). In the fully adjusted
regression models, adjustments were performed for age,
BMI, physical activity, and current smoking habits in both
sexes. All tests were two-sided, and a P value < 0.05 was
defined as statistically significant. The Stata 12 software
(StataCorp, Texas, USA) was used for all statistical analyses.
Results
Of the initial 2426 included participants, the data of 2380
individuals (1228 women and 1152 men) for the MetS,
BMD, and TBS were completed and considered for analysis.
The mean ± SD age of the individuals was 69.32 ± 6.35
(69.51 ± 6.40 for men and 69.14 ± 6.30 for women). The di-
agnosis of MetS was made for 1264 subjects (822 women and
442 men) and the prevalence of MetS was 66.94% in women
and 38.37% in men. The baseline characteristics were signif-
icantly different between the participants with MetS than
those without MetS in both sexes, except for daily physical
activity and current smoking in women and age, TC and LDL-
C in men (Table 1).
The mean BMD of the femoral neck, total hip, and lumbar
spine were significantly higher in subjects with MetS in both
sexes in comparison with those without MetS (P values <
0.001). Likewise, the prevalence of osteoporosis (based on
BMD) was significantly lower in individuals with MetS
(53.77% in women and 13.57% in men) vs. those without
MetS (68.47% in women and 29.01% in men) (Table 2). In
contrast, the mean lumbar spine TBS in both sexes was not
statistically different between participants with and without
MetS (P values ≥ 0.05). The prevalence of degraded bone
microarchitecture (based on TBS) in women was also not
statistically different between the two groups (with MetS,
32.85%; without MetS, 28.33%; P value = 0.108). However,
the prevalence of degraded bone microarchitecture in men
was significantly higher in patients with MetS (9.05%) com-
pared with those without MetS (4.08%) (Table 2).
In both sexes, there was a significant increase in femoral
neck, total hip, and spinal mean BMD with each increment in
the number of MetS components (P value < 0.001 for trend).
Similarly, the prevalence of osteoporosis significantly de-
creased when the number of MetS components increased (P
value < 0.001 for trend in men and women). When trend anal-
ysis was conducted for the mean TBS and the prevalence of
degraded bone microarchitecture, the only significant trend
observed was the preva lence of degraded bone
microarchitecture inmen (P value < 0.001 for trend) (Table 2).
In both sexes, the MetS had a significant positive relation-
ship with lumbar spine, femoral neck, and total hip mean
BMD in the univariable (unadjusted) linear regression model
(P values < 0.001); these significant positive relationships
were maintained after adjustments for age, physical activity,
and smoking status in all sites and in both sexes (models 1 and
2; P values < 0.001). However, when BMI was added to the
model (model 3), the statistical significance was canceled out
in femoral neck (P value = 0.071) and total hip (P value =
0.150) in women (Table 3). As demonstrated in
Supplementary Table 1, after addingMetS components (when
they reached five components), the positive association be-
tween MetS and mean BMD in women became significant
again in femoral neck (P value = 0.010) and in total hip (P
value = 0.049), even after adjustments for several factors, in-
cluding BMI (fully adjusted model). Univariable and multi-
variable logistic regression analyses (including BMI) also
confirmed a significant reversed relationship between the
prevalence of osteoporosis and MetS, irrespective of the par-
ticipants’ sex (P values < 0.05) (Table 4). In addition, after the
full adjustment, the reversed relationship between the preva-
lence of osteoporosis and the number of MetS components
still persisted (Supplementary Table 2). Finally, when the data
of men and women were pooled, the positive association of
MetS with BMD in all sites and the negative association of
MetS with the prevalence of osteoporosis remained significant
(P values < 0.001) in all the adjusted models (Supplementary
Tables 3 and 4).
In the initially unadjusted regression model, MetS was re-
lated to increased prevalence of degraded bone in men (OR =
2.337; P value = 0.001). However, no association was ob-
served either between MetS and the prevalence of degraded
bone microarchitecture in women or between MetS and mean
TBS in both sexes (P values ≥ 0.05). After the adjustment for
age (model 1), the prevalence of degraded bone
microarchitecture significantly increased in both sexes (in
women, OR = 1.349, P value = 0.028; in men, OR = 2.376,
P value = 0.001), and also, the MetS became negatively asso-
ciated with mean TBS in women (β = − 0.075; P value =
0.007). These associations persisted after the inclusion of
smoking status and physical activity in the age-adjusted
models (model 2; P values < 0.05) (Tables 3 and 4).
Moreover, when the number of MetS components increased,
the negative association between MetS and mean TBS be-
came significant in both sexes in the unadjusted model
(Supplementary Table 1) and remained significant after ad-
justments for age, physical activity, and smoking status (data
not shown). As shown in Supplementary Tables 3 and 4, the
pooled data of men and women also confirmed a significantly
lower TBS and higher prevalence of degraded bone
microarchitecture in those with MetS before and after adjust-
ments for age, sex, smoking status, and physical activity
(models 1 and 2; P values < 0.01). However, when BMI was
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added to the models (model 3 or the fully adjusted model),
all significant associations of MetS and the number of
MetS components with TBS values disappeared (P values
≥ 0.05) (Tables 3 and 4 as well as Supplementary
Tables 1, 2, 3, and 4).
In the multivariable logistic regression model, among the
MetS components, abdominal obesity, which was determined
by WC, had a strong positive association with osteoporosis
(OR = 0.423; P value < 0.001). Other MetS components, in-
cluding high glucose level (OR = 0.633; P value < 0.001),
high TG level (OR = 0.728; P value = 0.013), and high BP
(OR = 0.731; P value = 0.004) also had positive association
with osteoporosis. In contrast, abdominal obesity (OR =
3.089; P value < 0.001) was the only factor which applied
the negative effect of MetS on bone microarchitecture
(Table 5).
Discussion
The present study demonstrated that mean BMD in all three
sites was significantly higher and the prevalence of
osteoporosis (based on BMD) was also significantly lower
(more than 14%) in subjects with MetS than those without
MetS in both sexes. Moreover, we observed that with the
increasing number of MetS criteria, the BMD was further
increased in an incremental manner across all locations in
men and women. This positive association of MetS with
BMD was preserved after several adjustments (including
BMI) especially in men. The significant reverse association
between theMetS and the prevalence of osteoporosis was also
maintained after full adjustments in both sexes. In contrast to
the abovementioned findings, depending on the sex and the
adjustment model, a negative or no association was observed
between MetS and TBS.
Studies have reported inconsistent results about the effects
of MetS on BMD [11, 30]. Some of these controversies may
arise from differences in ethnicity, baseline characteristics of
participants, MetS definition criteria, the BMD measurement
methods, and DXA scanner manufacturers, or the adjusting
covariates which are used in various studies [10]. In a study
conducted by Jeon et al. [31] on 931 postmenopausal women,
those with MetS had significantly lower BMD at the femoral
neck and lumbar spine before or after adjustments. Hwang
Table 1 Clinical characteristics of the participants categorized by the presence of MetS
Variables Total Women Men
With MetS,
n = 1264
Without MetS,
n = 1116
P value With MetS,
n = 822
Without MetS,
n = 406
P value With MetS,
n = 442
Without MetS,
n = 710
P value
Age (years), mean
(SD)
68.86 (5.96) 69.84 (6.74) < 0.001 68.74 (5.82) 69.95 (7.11) 0.002 69.08 (6.20) 69.77 (6.52) 0.072
BMI (kg/m2), mean
(SD)
29.19 (4.75) 25.61 (4.32) < 0.001 29.73 (5.14) 26.65 (5.09) < 0.001 28.19 (3.72) 25.02 (3.69) < 0.001
Daily physical
activity (METs),
mean (SD)
30.78 (4.91) 31.28 (5.63) 0.021 30.80 (4.66) 30.80 (4.72) 0.995 30.74 (5.35) 31.56 (6.08) 0.021
Current smoker
(cigarette, hookah,
or pipe), n (%)
237 (18.76) 264 (23.70) 0.003 146 (17.78) 82 (20.25) 0.297 91 (20.59) 182 (25.67) 0.049
TC (mg/dl), mean
(SD)
183.65 (47.15) 180.48 (40.88) 0.082 188.68 (48.05) 194.50 (40.53) 0.036 174.30 (43.98) 172.46 (38.89) 0.458
TG (mg/dl), mean
(SD)
166.97 (77.45) 100.71 (38.16) < 0.001 162.78 (76.78) 97.46 (29.54) < 0.001 174.78 (78.18) 102.57 (42.22) < 0.001
HDL-C (mg/dl),
mean (SD)
42.17 (9.99) 50.20 (11.03) < 0.001 44.76 (9.77) 56.48 (10.84) < 0.001 37.37 (8.50) 46.61 (9.43) < 0.001
LDL-C (mg/dl),
mean (SD)
108.44 (40.23) 110.53 (34.90) 0.178 111.66 (41.50) 118.93 (35.99) 0.003 102.44 (37.06) 105.73 (33.35) 0.120
FPG (mg/dl), mean
(SD)
119.11 (49.44) 91.81 (26.59) < 0.001 117.38 (49.87) 88.43 (19.80) < 0.001 122.33 (48.54) 93.75 (29.63) < 0.001
WC (cm), mean (SD) 103.07 (10.62) 93.74 (11.55) <0.001 103.11 (11.07) 94.44 (13.17) < 0.001 103.00 (9.74) 93.34 (10.50) < 0.001
SBP (mmHg), mean
(SD)
143.09 (18.48) 135.88 (19.48) 0.001 142.44 (18.55) 133.39 (19.21) < 0.001 144.31 (18.30) 137.30 (19.51) < 0.001
DBP (mmHg), mean
(SD)
82.14 (8.57) 80.94 (8.65) < 0.001 81.28 (8.52) 79.86 (8.44) 0.006 83.72 (8.45) 81.55 (8.71) < 0.001
BMI body mass index, DBP diastolic blood pressure, FPG fasting plasma glucose, HDL-C high density lipoprotein-cholesterol, LDL-C low density
lipoprotein-cholesterol,MetSmetabolic syndrome, SD standard deviation, SBP systolic blood pressure, TC total cholesterol, TG triglyceride,WC waist
circumference
1978 Osteoporos Int (2020) 31:1975–1984
Ta
bl
e
2
B
on
e
he
al
th
st
at
us
of
th
e
pa
rt
ic
ip
an
ts
ba
se
d
on
th
e
pr
es
en
ce
of
M
et
S
an
d
th
e
nu
m
be
r
of
M
et
S
co
m
po
ne
nt
s
V
ar
ia
bl
es
P
ar
tic
ip
an
ts
N
um
be
r
of
M
et
S
cr
ite
ri
a
T
ot
al
W
ith
ou
tM
et
S
W
ith
M
et
S
P
va
lu
e
N
o
O
ne
T
w
o
T
hr
ee
F
ou
r
Fi
ve
P
va
lu
e
P
va
lu
e
fo
r
tr
en
d
W
om
en
n
=
12
28
n
=
40
6
n
=
82
2
n
=
25
n
=
10
7
n
=
27
4
n
=
35
4
n
=
31
1
n
=
15
7
L
um
ba
r
sp
in
e
B
M
D
(g
r/
cm
2
),
m
ea
n
(S
D
)
0.
81
(0
.1
4)
0.
77
(0
.1
5)
0.
83
(0
.1
4)
<
0.
00
1
0.
71
(0
.1
1)
0.
72
(0
.1
5)
0.
79
(0
.1
4)
0.
81
(0
.1
4)
0.
84
(0
.1
3)
0.
87
(0
.1
4)
<
0.
00
1
<
0.
00
1
Fe
m
or
al
ne
ck
B
M
D
(g
r/
cm
2
),
m
ea
n
(S
D
)
0.
59
(0
.1
1)
0.
57
(0
.1
1)
0.
60
(0
.1
1)
<
0.
00
1
0.
53
(0
.0
6)
0.
54
(0
.1
1)
0.
58
(0
.1
1)
0.
59
(0
.1
1)
0.
60
(0
.1
0)
0.
63
(0
.1
2)
<
0.
00
1
<
0.
00
1
T
ot
al
hi
p
B
M
D
(g
r/
cm
2
),
m
ea
n
(S
D
)
0.
76
(0
.1
3)
0.
73
(0
.1
3)
0.
77
(0
.1
2)
<
0.
00
1
0.
68
(0
.1
0)
0.
69
(0
.1
4)
0.
74
(0
.1
3)
0.
75
(0
.1
3)
0.
78
(0
.1
1)
0.
80
(0
.1
3)
<
0.
00
1
<
0.
00
1
a O
st
eo
po
ro
si
s,
n
(%
)
72
0
(5
8.
63
)
27
8
(6
8.
47
)
44
2
(5
3.
77
)
<
0.
00
1
22
(8
8.
00
)
82
(7
6.
64
)
17
4
(6
3.
50
)
22
0
(6
2.
15
)
16
0
(5
1.
45
)
62
(3
9.
49
)
<
0.
00
1
<
0.
00
1
L
um
ba
r
sp
in
e
T
-s
co
re
≤
−2
.5
,n
(%
)
50
7
(4
1.
29
)
21
2
(5
2.
22
)
29
5
(3
5.
89
)
<
0.
00
1
16
(6
4.
00
)
70
(6
5.
42
)
12
6
(4
5.
99
)
16
1
(4
5.
48
)
95
(3
0.
55
)
39
(2
4.
84
)
<
0.
00
1
<
0.
00
1
Fe
m
or
al
ne
ck
T
-s
co
re
≤
−2
.5
,n
(%
)
58
8
(4
7.
99
)
23
3
(5
7.
53
)
35
5
(4
3.
19
)
<
0.
00
1
20
(8
3.
33
)
68
(6
3.
55
)
14
5
(5
2.
92
)
17
5
(4
9.
44
)
12
8
(4
1.
16
)
52
(3
3.
12
)
<
0.
00
1
<
0.
00
1
T
ot
al
hi
p
T
-s
co
re
≤
−2
.5
,n
(%
)
21
9
(1
7.
85
)
10
1
(2
4.
94
)
11
8
(1
4.
36
)
<
0.
00
1
9
(3
7.
5)
37
(3
4.
58
)
55
(2
0.
07
)
64
(1
8.
08
)
37
(1
1.
90
)
17
(1
0.
83
)
<
0.
00
1
<
0.
00
1
T
B
S
(L
1-
L
4)
,m
ea
n
(S
D
)
1.
24
(0
.0
9)
1.
25
(0
.0
8)
1.
24
(0
.0
9)
0.
05
8
1.
28
(0
.0
7)
1.
24
(0
.0
8)
1.
25
(0
.0
8)
1.
24
(0
.0
9)
1.
24
(0
.0
9)
1.
24
(0
.0
9)
0.
18
1
0.
17
5
b
D
eg
ra
de
d
bo
ne
m
ic
ro
ar
ch
ite
ct
ur
e,
n
(%
)
38
5
(3
1.
35
)
11
5
(2
8.
33
)
27
0
(3
2.
85
)
0.
10
8
5
(2
0.
00
)
31
(2
8.
97
)
79
(2
8.
83
)
12
4
(3
5.
03
)
10
1
(3
2.
48
)
45
(2
8.
66
)
0.
35
6
0.
43
7
M
en
n
=
11
52
n
=
71
0
n
=
44
2
n
=
81
n
=
28
5
n
=
34
4
n
=
27
4
n
=
12
4
n
=
44
L
um
ba
r
sp
in
e
B
M
D
(g
r/
cm
2
),
m
ea
n
(S
D
)
0.
99
(0
.1
7)
0.
96
(0
.1
6)
1.
04
(0
.1
7)
<
0.
00
1
0.
92
(0
.1
8)
0.
95
(0
.1
6)
0.
98
(0
.1
6)
1.
03
(0
.1
8)
1.
04
(0
.1
8)
1.
09
(0
.1
4)
<
0.
00
1
<
0.
00
1
Fe
m
or
al
ne
ck
B
M
D
(g
r/
cm
2
),
m
ea
n
(S
D
)
0.
73
(0
.1
3)
0.
71
(0
.1
3)
0.
76
(0
.1
4)
<
0.
00
1
0.
68
(0
.1
3)
0.
71
(0
.1
3)
0.
72
(0
.1
3)
0.
76
(0
.1
3)
0.
75
(0
.1
5)
0.
81
(0
.1
6)
<
0.
00
1
<
0.
00
1
T
ot
al
hi
p
B
M
D
(g
r/
cm
2
),
m
ea
n
(S
D
)
0.
94
(0
.1
4)
0.
92
(0
.1
4)
0.
99
(0
.1
4)
<
0.
00
1
0.
88
(0
.1
4)
0.
91
(0
.1
4)
0.
94
(0
.1
4)
0.
98
(0
.1
4)
0.
99
(0
.1
4)
1.
03
(0
.1
6)
<
0.
00
1
<
0.
00
1
a O
st
eo
po
ro
si
s,
n
(%
)
26
6
(2
3.
09
)
20
6
(2
9.
01
)
60
(1
3.
57
)
<
0.
00
1
33
(4
0.
74
)
92
(3
2.
28
)
81
(2
3.
55
)
39
(1
4.
23
)
18
(1
4.
52
)
3
(6
.8
2)
<
0.
00
1
<
0.
00
1
L
um
ba
r
sp
in
e
T
-s
co
re
≤
−2
.5
,n
(%
)
17
8
(1
5.
45
)
13
9
(1
9.
58
)
39
(8
.8
2)
<
0.
00
1
26
(3
2.
10
)
63
(2
2.
11
)
50
(1
4.
53
)
27
(9
.8
5)
10
(8
.0
6)
2
(4
.5
5)
<
0.
00
1
<
0.
00
1
Fe
m
or
al
ne
ck
T
-s
co
re
≤
−2
.5
,n
(%
)
16
7
(1
4.
51
)
12
8
(1
8.
05
)
39
(8
.8
2)
<
0.
00
1
23
(2
8.
75
)
58
(2
0.
35
)
47
(1
3.
66
)
22
(8
.0
3)
15
(1
2.
10
)
2
(4
.5
5)
<
0.
00
1
<
0.
00
1
T
ot
al
hi
p
T
-s
co
re
≤
−2
.5
,n
(%
)
20
(1
.7
4)
18
(2
.5
4)
2
(0
.4
5)
0.
00
8
4
(5
.0
0)
10
(3
.5
1)
4
(1
.1
6)
2
(0
.7
3)
0
(0
.0
0)
0
(0
.0
0)
0.
00
8
<
0.
00
1
T
B
S
(L
1-
L
4)
,m
ea
n
(S
D
)
1.
35
(0
.0
9)
1.
36
(0
.0
9)
1.
35
(0
.1
0)
0.
12
3
1.
37
(0
.0
7)
1.
36
(0
.0
8)
1.
35
(0
.0
9)
1.
35
(0
.1
0)
1.
34
(0
.1
0)
1.
34
(0
.0
9)
0.
23
3
0.
05
3
b
D
eg
ra
de
d
bo
ne
m
ic
ro
ar
ch
ite
ct
ur
e,
n
(%
)
69
(5
.9
9)
29
(4
.0
8)
40
(9
.0
5)
<
0.
00
1
2
(2
.4
7)
6
(2
.1
1)
21
(6
.1
0)
23
(8
.3
9)
15
(1
2.
10
)
2
(4
.5
5)
0.
00
1
<
0.
00
1
B
M
D
bo
ne
m
in
er
al
de
ns
ity
,M
et
S
m
et
ab
ol
ic
sy
nd
ro
m
e,
SD
st
an
da
rd
de
vi
at
io
n,
TB
S
tr
ab
ec
ul
ar
bo
ne
sc
or
e
a
O
st
eo
po
ro
si
s
(b
as
ed
on
B
M
D
)
co
ns
id
er
ed
T
-s
co
re
≤
−
2.
5
in
th
e
to
ta
lh
ip
,f
em
or
al
ne
ck
,o
r
lu
m
ba
r
sp
in
e
b
D
eg
ra
de
d
bo
ne
m
ic
ro
ar
ch
ite
ct
ur
e
co
ns
id
er
ed
lu
m
ba
r
T
B
S
≤
1.
2
1979Osteoporos Int (2020) 31:1975–1984
Table 3 Assessing the
association of MetS with BMD
and TBS using the linear
regression analysis in men and
women
MetS (yes/no) Women Men
B SE β P value B SE β P value
Lumbar spine BMD
Unadjusted 0.062 0.009 0.204 <0 .001 0.077 0.010 0.218 < 0.001
aModel 1 0.054 0.008 0.176 < 0.001 0.077 0.010 0.217 < 0.001
bModel 2 0.053 0.008 0.175 < 0.001 0.073 0.010 0.207 < 0.001
cModel 3 0.023 0.008 0.075 0.003 0.039 0.011 0.111 < 0.001
Femoral neck BMD
Unadjusted 0.034 0.007 0.142 < 0.001 0.050 0.008 0.180 < 0.001
aModel 1 0.025 0.006 0.104 < 0.001 0.046 0.008 0.166 < 0.001
bModel 2 0.025 0.006 0.108 < 0.001 0.046 0.008 0.167 < 0.001
cModel 3 0.011 0.006 0.046 0.071 0.026 0.008 0.095 0.001
Total hip BMD
Unadjusted 0.042 0.008 0.156 < 0.001 0.066 0.008 0.226 < 0.001
aModel 1 0.031 0.007 0.115 < 0.001 0.063 0.008 0.214 < 0.001
bModel 2 0.032 0.007 0.118 < 0.001 0.063 0.008 0.213 < 0.001
cModel 3 0.010 0.007 0.035 0.150 0.037 0.009 0.125 < 0.001
TBS
Unadjusted − 0.010 0.005 − 0.054 0.058 − 0.009 0.006 − 0.045 0.123
aModel 1 − 0.014 0.005 − 0.075 0.007 − 0.010 0.006 − 0.052 0.077
bModel 2 − 0.014 0.005 − 0.073 0.009 − 0.005 0.005 − 0.027 0.349
cModel 3 − 0.010 0.006 − 0.055 0.059 0.004 0.006 0.024 0.442
β standardized regression coefficient, B unstandardized regression coefficient, BMD bone mineral density,MetS
metabolic syndrome, SE standard error
aModel 1: adjusted for age
bModel 2: adjusted for age, physical activity, and smoking status
cModel 3 or final model: adjusted for age, physical activity, smoking status, and BMI
Table 4 Assessing the association ofMetS with osteoporosis and the degraded bonemicroarchitecture in men and women using the logistic regression
analysis
Sex Women Men
MetS (yes/no) Osteoporosis* Degraded bone
microarchitecture**
Osteoporosis* Degraded bone
microarchitecture**
OR 95% CI P value OR 95% CI P value OR 95% CI P value OR 95% CI P value
Unadjusted 0.536 0.417–0.688 < 0.001 1.238 0.954–1.606 0.108 0.384 0.280–0.528 < 0.001 2.337 1.426–3.828 0.001
aModel 1 0.562 0.433–0.729 < 0.001 1.349 1.033–1.762 0.028 0.392 0.285–0.539 < 0.001 2.376 1.448–3.897 0.001
bModel 2 0.550 0.424–0.715 < 0.001 1.319 1.008–1.724 0.043 0.389 0.281–0.538 < 0.001 2.313 1.405–3.807 0.001
cModel 3 0.707 0.537–0.930 0.013 1.078 0.816–1.426 0.596 0.563 0.398–0.797 0.001 1.268 0.737–2.182 0.392
CI confidence interval, MetS metabolic syndrome, OR odds ratio
*Osteoporosis (based on BMD) considered as T-score ≤ −2.5 in the total hip, femoral neck, or lumbar spine
**Degraded bone microarchitecture considered as lumbar TBS ≤ 1.2
aModel 1: adjusted for age
bModel 2: adjusted for age, physical activity, and smoking status
cModel 3 or final model: adjusted for age, physical activity, smoking status, and BMI
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et al. [16] also reported the same results and showed that the
unadjusted and adjusted lumbar spine BMD was significantly
lower in those with MetS. Furthermore, they demonstrated
that vertebral BMD further declined (P value = 0.004) as the
number of MetS components increased [16]. However, the
results of many studies, especially those which were conduct-
ed in the Caucasian population were in line with the present
study and indicated a higher BMD in individuals with MetS,
at least in crude or age-adjusted analyses [10, 30]. In Rancho
Bernardo Study, Von Muhlen et al. [32] evaluated the associ-
ation of MetS with bone health in 417 men and 671 women.
They demonstrated that age-adjusted BMD was significantly
higher in total hip and lumbar spine in both sexes. The age-
adjusted BMD in femoral neck was also higher in those with
MetS but did not reach statistical significance (P value = 0.05
for males and P value = 0.06 for females). However, they
showed that after the addition of BMI to the adjusted factors,
these associations were reversed, and MetS was accompanied
by lower BMD in all locations (femoral neck, total hip, and
lumbar spine) with significant results for the femoral neck in
males (P value = 0.02) [32]. In another large study, Kinjo et al.
[14] examined the relationship between femoral neck BMD
and MetS in a population-based US sample from the Third
National Health and Nutrition Examination Survey
(NHANES III). They demonstrated that the adjusted femoral
neck BMD (BMI is not included in adjustment factors) was
significantly higher among individuals with MetS than in
those in the control group. However, when the adjusted
BMD was stratified by BMI, the femoral neck BMD was
similar between the two groups. Similar to our results, Kinjo
et al. also reported a significant positive trend in femoral neck
BMD when the components of MetS increased [14]. In the
MINOS Study, Szulc et al. [33] evaluated the association of
MetS and bone health in 762 men (aged 50–85) followed up
for 10 years. They observed a significantly higher BMD in the
lumbar spine, total hip, and femoral neck in those with MetS.
However, after adjustments for several factors, including
BMI, men withMetS had significantly lower BMD at the total
hip and femoral neck. In the fully adjusted model, the lumbar
spine BMD was also lower in those with MetS but did not
reach statistical significance [33]. Hernandez et al. [34] also
demonstrated that MetS was related to higher age-adjusted
BMD in femoral neck, total hip, and lumbar spine in postmen-
opausal women and this positive effect was canceled out after
adjustment for BMI at the spine and femoral neck.
Nevertheless, the bone mass difference in total hip remained
significant even after adjustments for age and BMI in women
(P value = 0.047). Based on their results, the MetS had no
significant effect on BMD in any site before or after adjust-
ments in men [34].
As demonstrated above, many studies concluded that BMI
or weight is the main factor that determined the effect of MetS
on BMD and after adjustment for it, the positive effect of
MetS tended to disappear [30]. On the contrary, our results
showed that even after adjustments for several factors, includ-
ing BMI, the prevalence of osteoporosis (based on BMD) is
significantly lower in those with MetS than those without
MetS in both sexes. Likewise, in the fully adjusted models,
the positive association of MetS with BMD remained with
significant results for all sites in males and for the lumbar
Table 5 Multivariable logistic
regression analysis between each
one of the MetS components and
osteoporosis as well as the
degraded bone microarchitecture
in all subjects
Total
MetS components* aOsteoporosis bDegraded bone microarchitecture
OR 95% CI P value OR 95% CI P value
cAbdominal obesity 0.423 0.325–0.552 < 0.001 3.089 2.242–4.258 < 0.001
dHigh glucose 0.633 0.521–0.770 < 0.001 1.159 0.921–1.457 0.208
eHigh BP 0.728 0.566–0.934 0.013 1.110 0.802–1.537 0.530
fHigh TG 0.731 0.591–0.904 0.004 0.803 0.624–1.032 0.087
gLow HDL-C 0.851 0.698–1.037 0.109 0.867 0.686–1.096 0.234
BP blood pressure, CI confidence interval, FPG fasting plasma glucose, HDL-C high density lipoprotein-cho-
lesterol, MetS metabolic syndrome, OR odds ratio, TG triglyceride, WC waist circumference
*Adjusted for age, sex, physical activity, and smoking status
a Osteoporosis (based on BMD) considered as T-score ≤ −2.5 in the total hip, femoral neck, or lumbar spine
bDegraded bone microarchitecture considered as lumbar TBS ≤ 1.2
cWC > 102 cm in men or > 88 cm in women
d FPG ≥ 100 mg/dl or on drug treatment for elevated glucose
e BP ≥ 130/85 mmHg or on antihypertensive medications
f TG ≥ 150 mg/dl
g HDL-C < 40 mg/dl in men or < 50 mg/dl in women
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spine in females. The reasons for these sex- and site-specific
differences in the relationship between MetS and BMD in the
fully adjusted model are not known. However, as shown by
Felson et al. in Framingham study, the greater effect of BMI
on BMD in women than in men may explain some of these
sex differences. Felson et al. suggested that BMD in postmen-
opausal women have greater dependency on estrogen produc-
tion of adipose tissue than in men with intact gonadal function
[35]. Finally, our results showed that besides the strong posi-
tive association of WC with BMD, other components of
MetS, including high TG, high glucose level, and high BP,
also had positive influence on BMD. These findings indicated
that MetS may be related to higher BMD irrespective of BMI
especially in men.
Most studies have evaluated the effect of MetS on BMD,
but the data on its influence on bone quality, especially for
TBS, is scarce. Our study indicated that despite the positive
association between MetS and BMD, the bone quality (based
on TBS) is either not associated or negatively associated with
MetS. A study conducted by Povoroznyuk et al. [36] achieved
the same results. They showed that postmenopausal women
withMetS had significantly higher BMD in all sites and lower
mean TBS in comparison with pre-obese females [36]. Our
study also showed that the possible negative impact of MetS
on bone quality is mainly driven by BMI and/or WC.
The paradoxical effect of MetS on bone quality (no or neg-
ative effect) and quantity (positive effect) may be explained by
a different way through which obesity may act on bone health.
Traditionally, obesity has been considered as a protective factor
against osteoporosis, and a positive association between BMI
andBMDhas been reported [20, 37]. However, recent pieces of
evidence proposed that obesity, especially visceral adipose tis-
sue, may have detrimental effects on bone health and may be
associated with impaired bone microarchitecture [38]. For in-
stance, Lv et al. investigated the relationship between body fat
and its distribution on TBS and BMD. They concluded that fat
mass especially visceral fat has a negative impact on TBS and
bone microarchitecture, while it improves BMD through me-
chanical loading [39]. The negative influence of visceral fat on
bone quality is also shown at the tissue level in transiliac bone
biopsies obtained from healthy premenopausal women with
different amounts of central adiposity [19]. Several potential
mechanisms have been suggested to account for the complex
relationship between abdominal obesity (visceral fat) and bone
metabolism. Mechanical loading is the main mechanism by
which abdominal obesity contributes to higher BMD in obese
individuals [20]. In addition, a higher insulin and 17β-estradiol
level caused by abdominal obesity may have positive effects on
BMD [14, 40]. Visceral fat may also increase bone mass by the
regulation of several adipokines, including leptin and
adiponectin [40]. On the other hand, the detrimental effect of
central obesity on osteoblast activity and/or the induction of
low-grade inflammation by adipose tissue, which affects bone
remodeling, may in turn reduce bone quality [19, 41, 42].
Moreover, central adiposity is associated with dysregulation
of the growth hormone (GH)/insulin-like growth factor (IGF)-
1 axis and lower serum IGF-1 level. Low levels of IGF-1, an
anabolic hormone for osteoblast lineage, may adversely affect
bone formation and cause poor bone quality [19]. Finally, those
with abdominal obesity generally have lower physical activity
which has negative effects on bone health [43].
Another possible reason for this discrepancy between the
impact of MetS on BMD and TBS is related to the effect of
BMI on the TBS measurement accuracy. In other words, TBS
is not considered valid for individuals with a high BMI (>
37 kg/m2) [28]. Based on Langsetmo et al.’s [28] report, de-
spite the fact that TBS is inversely associated with BMI, when
compared with lumbar volumetric BMD, it was observed that
the bone quality does not decrease as depicted by TBS and
therefore TBS may underestimate the bone quality and
strength in those with a high BMI. Nevertheless, in our study,
after the exclusion of subjects with BMI > 37 kg/m2, theMetS
did not have a positive effect on TBS values (data not shown).
Our study was strengthened by taking a large representative
sample of the elderly population from both sexes. Moreover, we
assessed the effect of MetS on bone status by both BMD and
TBS. However, this research had several limitations, including
the cross-sectional design, which did not allow assessing the
causality, and also the lack of fracture data. Studies are contro-
versial in regard to the effect ofMetS on the risk of bone fracture.
However, two published meta-analyses which evaluated the ef-
fect MetS on bone fractures concluded that MetS reduced the
risk of fracture [13, 44]. If these data are confirmed, the lower
rate of fractures in individuals with MetS may be explained by
the strong positive effect of MetS on BMD, which offsets its
potentially negative impact on bone quality. Another limitation
of our study is the possible effect of lumbar spine osteoarthritis, a
prevalent disease in old and obese individuals, on spine BMD
which may lead to an artifactually elevated spine BMD.
However, as both hip (total hip and femoral neck) and lumbar
spine BMDwere increased in patients withMetS compared with
those without, it seems that MetS is actually related to higher
BMD. Based on Kolta et al.’s report, TBS is not affected by
lumbar spine degenerative changes [45].
In conclusion, our findings suggest that MetS is associated
with higher BMD in both sexes. This positive effect on BMD
is maintained even after adjustments for several factors, in-
cluding BMI, especially in men. In addition, after an increase
in the number of MetS components, the positive effect of
MetS on BMD is further increased. In contrast, MetS may
have detrimental or no effect on bone quality as measured
by TBS and the possible negative influence of MetS on TBS
is mainly driven by BMI and/orWC. Further studies are need-
ed to confirm these paradoxical effects of MetS on BMD and
bone quality and to determine the net impact of MetS on bone
health and fracture outcome.
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